RT @drdavidliew: Cancer risk with tofacitinib vs TNFi in RA: we learned at #ACR21 that CV-enriched pts: risk (ORAL Surve

Cancer risk with tofacitinib vs TNFi in RA: we learned at #ACR21 that CV-enriched pts: risk (ORAL Surveillance) all comers: no risk (STAR-RA) French national healthcare database #ACR22 looks at all comers: nothing to separate tofa and TNFi. Risk begets risk ABST1984 @RheumNow https://t.co/0GG04NSP3D https://t.co/nwQz7fx21M